CDC recommends Novavax COVID-19 vaccine for adolescents

Last month, CDC Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo that Novavax’s COVID-19 vaccine be used as another primary series option for adolescents ages 12 through 17.
Novavax’s COVID-19 vaccine, which is available now, is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adolescents.
Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers.